market access

News

All EU Flags in front of the European Parliament, Flags in front of the European Parliament, Strasbourg, Alsace, France

Survey shows patients wait six times longer than EU neighbou...

Patients in some European countries are waiting up to six times longer for access to medicines than their neighbours, according to a survey by Europe’s pharma trade body.

News

Germany first in EU to get Novartis' SMA gene therapy, costi...

Novartis is set to launch its one-off gene therapy Zolgensma for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA) in Germany at the start of July priced at 1,945,000 euro

News

NICE rejects Sanofi's Cablivi for rare blood disorder TTP

NICE has rejected Sanofi’s Cablivi (caplacizumab) for the rare blood disorder thrombotic thrombocytic purpura (TTP) in first draft guidance.

News

Jeff Anderson joins OPEN Health in European lead role

Jeff Anderson has joined OPEN Health as European Lead for its OPEN VIE and Pharmerit Europe practices.

Views & Analysis

Market access in the time of COVID-19

COVID-19 has left no part of life untouched, including health technology assessment (HTA) and other payer agency activities, and it will likely have a lasting impact on market access.

News

Gilead's remdesivir could be $7.7bn blockbuster - analyst

An influential analyst has upped his previously cautious assessment of the sales potential of Gilead’s COVID-19 drug remdesivir, saying sales could reach $7.7 billion in 2022.

Survey shows patients wait six times longer than EU neighbou...

Germany first in EU to get Novartis' SMA gene therapy, costi...

NICE rejects Sanofi's Cablivi for rare blood disorder TTP

Jeff Anderson joins OPEN Health in European lead role

Market access in the time of COVID-19

Gilead's remdesivir could be $7.7bn blockbuster - analyst

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

market access

Editor's Picks